Navigation Links
Greenway Medical Technologies Continues Record Setting Growth
Date:2/6/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ent and Emerging Drugs Will Not Surpass Vyvanse as...port From Decision Resources , , WALTHAM, Mass....f the world,s leading research and advisory firms ...finds that physicians indicate there is an unmet n...approved for adult attention-deficit/hyperactivity...
(Date:1/8/2009)...REDWOOD CITY, Calif., Jan. 8 /PRNewswire-FirstCall... announced the appointment of Kimberly J. Popovits...and chief operating officer,Popovits is now the ... G.,Bradley Cole has been appointed as chief oper...ompany,s chief financial officer, reporting to Pop...
(Date:1/8/2009)...tPoint (SharePoint) and FirstDoc (Documentum) Solu...ollaboration Capabilities , , FALLS CHURCH, Va....ced today new releases of its FirstPoint and First... adding features designed to support the systemati...ycle and the growing collaboration needs of global...
(Date:1/8/2009)...ted funds will force hospitals to reconsider or de...Millennium Research Group , , WALTHAM, Mass., J...arch Group,s (MRG,s) US Markets for PACS, RIS, an...ing many health care facilities will significantly...unication systems (PACS), radiology information sy...
Breaking Medicine News(10 mins):Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2
...s of unpleasant experiences with unhealthy foods c...zabeth Loftus of the University of California, Irv...they had been sick after eating strawberry ice cre... colleagues gave 228 undergraduate students questi...
...blication of the UN report shows staggering figure...h also included India. The Indian Government thoug...g ‘Anytime Condom” vending machines in commonly ac...he bus stands, railway stations and public bathroo...
...n the latest issue of Harvard Women’s Health Watch...rienced by some women in their menopausal or postm...menopausal women—and to many who are in peri-menop...t flashes tend to come on suddenly and last from o...
...ivered their firstborn by caesarean were less like...neous natural delivery says a new British study. R...iversity of Aberdeen, Britain, followed women who ...d - multiple births were excluded - between 1980 a...
Other Medicine News:Health News:Unpleasant Memory of Food could Be Used to Treat Obesity 2Health News:Condom Vending Machines Increasing Sexual Assaults On Women 2Health News:Insight for Hot Flashes In Postmenopausal Women 2
(Date:1/8/2009)...E, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ -...oprietary nucleic acid assays, today announced tha...ral Quantitative Assay are complete. , , Under... linearity, specificity and reproducibility and ro...etermined. The data obtain agreed with internally ...
(Date:1/7/2009)...K, Md., Jan. 7 ImQuest Life Scienc... IND application to the Food and Drug Administrati...d pyrimidinedione HIV inhibitor IQP-0410. ImQuest ...e first quarter of 2009. IQP-0410 is a novel small... a nonnucleoside reverse transcriptase inhibitor (...
(Date:1/6/2009)...ignificance of AHCC for maintaining a healthy immu...e/ -- A recently published study in Nutrition and... Medical University in Osaka, Japan has shown that... immune function by increasing the number of dendr... system responsible for presenting foreign substan...
(Date:1/6/2009)...IPPANY, N.J., Jan. 6 Pacira Pharma...utical company, announced today that enrollment,h...trials to evaluate the,safety and efficacy of a s...,(DepoBupivacaine) for prolonged postoperative an...rrhoidectomy and in total knee,arthroplasty (TKA)...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Derma Sciences Announces Agreement With MedAssets for MEDIHONEY 28TM 29 Wound 26 Burn Dressings 4808 1Derma Sciences Announces Agreement With MedAssets for MEDIHONEY 28TM 29 Wound 26 Burn Dressings 4808 2Derma Sciences Announces Agreement With MedAssets for MEDIHONEY 28TM 29 Wound 26 Burn Dressings 4808 3Derma Sciences Announces Agreement With MedAssets for MEDIHONEY 28TM 29 Wound 26 Burn Dressings 4808 4Heart derived stem cells develop into heart muscle 17529 1Heart derived stem cells develop into heart muscle 17529 2DFG welcomes decision on stem cell research by German parliament 3009 1New VP of Operations Enhances The Beryl Companies Leadership Team 17523 1New VP of Operations Enhances The Beryl Companies Leadership Team 17523 2
... Clinical Trial in Type 2,Diabetes Patients Announ... - Transition,Therapeutics Inc. ("Transition") , t...ase IIa clinical trial indicating that 4-weeks of,...N.T.(TM), showed,sustained reductions in blood glu...(HbA1c), for 6 months post-treatment. The type 2,d...
..., 2007 - Cytogen,Corporation (NASDAQ: CYTO) report...dy evaluating QUADRAMET(R) (samarium Sm-153,lexidr...lcade(R),Millennium Pharmaceuticals, Inc.) in pat... patients were presented today in a,poster titled,...Sam) in Multiple Myeloma," by James Berenson, M.D....
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole.
Volk's super series slit lamp biomicroscopy lenses. General retinal scanning situations. Provide unprecedented fundus diagnostic capability, specifically addressing maximum potential field of view, f
Volk indirect lenses. Standard BIO examinations.
This contact class is particularly suitable for use with slit lamps which have a smaller distance between the eye and the reduction prism than the Haag-Streit 900, mirror: 3, area: fundus / iridocorn
Medicine Products: